Tag: CIMZIA
CIMZIA approved for use by Health Canada
UCB Canada has announced that CIMZIA (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial spondyloarthritis (nr-axSpA), has been approved for...
CIMZIA effective in treating axial spondyloarthritis patients
CIMZIA (certolizumab pegol) is the first therapy to demonstrate positive results in a 52-week, placebo controlled non-radiographic axial spondyloarthritis study. The positive topline results...